A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1799 details |
| Primary information | |
|---|---|
| ThPP ID | Th1193 |
| Therapeutic Peptide/Protein Name | Turoctocog alfa |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII. It was first launched in Germany in January 2014 and has been approved in the US, EU and Japan |
| Indication/Disease | In the safety and efficacy trial for prevention and treatment of bleeds, in hemophilia patients |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Zonovate |
| Company | Novo Nordisk Canada Inc |
| Brand Discription | It is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. It s produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII. It was first launched in Germany in January 2014 and has been approved in the US, EU and Japan. |
| Prescribed for | Treatment and control of bleeding episodes; Perioperative management; Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. |
| Chemical Name | |
| Formulation | Zonovate®is available in strengths of 250, 500, 1000, 1500, 2000 or 3000 IU/vial. The solvent for reconstitution of Zonovate® is 0.9% sodium chloride solution and is supplied as a clear colorless solutionin a prefilled syringe. |
| Physcial Appearnce | sterile, non-pyrogenic, white or slightly yellow powder |
| Route of Administration | Intravenous |
| Recommended Dosage | in minor Degree of Hemorrhage 20-40 IU/dl required. Repeat every 12 to 24 hours, at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved. In major Life threatening hemorrhages 60-100 IU/dl required with repeated injection every 8 to 24 hours until threat is resolved |
| Contraindication | Hypersensitivity |
| Side Effects | NA |
| Useful Link | http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Zonovate_PM_English.pdf |
| PubMed ID | 22812621, 28198071, 27904904, 27899309, 27620499, 27445511, 27291066, 27241682, 27152926 |
| 3-D Structure | N.A. |